Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc. has demonstrated strong financial momentum, reporting a 98% year-over-year revenue growth to $13.1 million in the third quarter, driven by a significant increase in surgeon users, which grew over 70% year-over-year. The company's Gross Margin (GM) of 75.9% exceeded forecasts by 250 basis points, attributed to lower contract manufacturing costs and a reduction in inventory reserve expenses, indicating operational efficiency. Furthermore, Carlsmed is positioned to tap into a substantial $13.4 billion market opportunity in lumbar fusion, with plans to expand into the cervical spine market by 2026, thus sustaining a projected revenue compound annual growth rate (CAGR) exceeding 50% through 2028.

Carlsmed Inc. faces several fundamental challenges that contribute to a negative outlook on its stock, including an estimated cervical revenue of $2.9 million for FY26, which falls short of the $3.4 million previously projected, indicating potential difficulties in market acceptance of its Aprevo technology. Additionally, the company may encounter headwinds from a slower adoption rate by new surgeons, lower growth rates in the overall spine market, and faster-than-anticipated degradation of average selling prices (ASP), compounded by higher operating expenses than previously modeled. Furthermore, the competitive landscape posed by larger industry players and potential reimbursement changes could further impair the economic viability and pricing strategies for Aprevo, resulting in an EBITDA loss of $30.7 million.